NYSE:CBM - Cambrex Stock Price, News & Analysis

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) released its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to the consensus estimate of $132.78 million. Cambrex had a net margin of 9.41% and a return on equity of 8.20%. The company's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.76 earnings per share. View Cambrex's Earnings History.

5 equities research analysts have issued 1-year price targets for Cambrex's shares. Their predictions range from $43.00 to $60.00. On average, they expect Cambrex's share price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.5%. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

News stories about CBM stock have trended negative on Sunday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cambrex earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cambrex.

Some companies that are related to Cambrex include Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK) and Mirati Therapeutics (MRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), Gilead Sciences (GILD), NVIDIA (NVDA), CVS Health (CVS), Juno Therapeutics (JUNO), Western Digital (WDC), Under Armour (UAA) and Broadcom (AVGO).

Cambrex's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.86%), Vanguard Group Inc. (10.41%), William Blair Investment Management LLC (7.84%), Bank of New York Mellon Corp (3.57%), Price T Rowe Associates Inc. MD (1.91%) and Northern Trust Corp (1.90%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Invesco Ltd., Janus Henderson Group PLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Natixis Advisors L.P., Man Group plc and SG Americas Securities LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

CBM stock was bought by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Nuveen Asset Management LLC, BlackRock Inc., Ontario Teachers Pension Plan Board, Scout Investments Inc., Public Employees Retirement Association of Colorado, Global Alpha Capital Management Ltd. and Vanguard Group Inc.. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $59.89.

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

The official website for Cambrex is http://www.cambrex.com/.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]